Edwards Lifesciences Co. (NYSE:EW - Free Report) - Stock analysts at Zacks Research increased their Q2 2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a report issued on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $0.62 for the quarter, up from their prior forecast of $0.61. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences' FY2025 earnings at $2.43 EPS and Q1 2026 earnings at $0.67 EPS.
EW has been the subject of a number of other research reports. Royal Bank of Canada increased their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research report on Thursday, December 5th. The Goldman Sachs Group boosted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, December 5th. Oppenheimer reissued an "outperform" rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Morgan Stanley reissued an "equal weight" rating and set a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the company a "hold" rating in a report on Thursday, December 5th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $78.65.
View Our Latest Report on Edwards Lifesciences
Shares of NYSE EW opened at $73.32 on Monday. The firm has a 50-day simple moving average of $69.42 and a two-hundred day simple moving average of $73.90. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $43.24 billion, a P/E ratio of 10.58, a PEG ratio of 3.63 and a beta of 1.12. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts' consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter in the previous year, the company earned $0.59 EPS. Edwards Lifesciences's revenue for the quarter was up 8.9% on a year-over-year basis.
In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,000 shares of company stock valued at $2,323,150. 1.29% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Edwards Lifesciences by 9.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company's stock valued at $31,571,000 after acquiring an additional 40,348 shares in the last quarter. AIA Group Ltd raised its position in shares of Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company's stock worth $49,461,000 after acquiring an additional 358,556 shares in the last quarter. RiverPark Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 58.1% in the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company's stock valued at $1,362,000 after buying an additional 7,583 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in Edwards Lifesciences by 40.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 36,745 shares of the medical research company's stock valued at $3,394,000 after buying an additional 10,492 shares in the last quarter. Finally, Banque Cantonale Vaudoise raised its stake in Edwards Lifesciences by 46.9% in the third quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company's stock valued at $5,353,000 after buying an additional 25,886 shares during the last quarter. 79.46% of the stock is owned by institutional investors.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.